Hyperion DeFi enters its September-quarter report needing to prove that last quarter's scramble was a pivot and not a patch. In May, the switch from USDH to USDC on Hyperliquid wiped out two house agreements and idled 800,000 hype tokens. Management responded within weeks, moving 1 million tokens into new deals with SKU and Entropy that it said carry better economics. Thursday's results, due before the open on November 12, are the first full quarter to show whether that redeployment actually earns more than what it replaced.
The usual Street yardsticks offer little help. The lone EPS estimate on record, $999 a share, is plainly a placeholder rather than a real forecast, and the implied growth rate built on it is meaningless. No credible revenue consensus exists either, against $0.3 million in the year-ago quarter and $0.4 million last quarter. Reported earnings are also a weak guide. Last quarter's $0.92 per share, versus $0.05 a year earlier, mostly reflected the value of the hype treasury, with net asset value nearly doubling to $134 million. The figure that matters is management's own target: adjusted gross profit of $5 million to $7 million for fiscal 2026, raised from $4 million to $6 million earlier in the year and only reaffirmed in August.
That target leaves little room for drift. Hyperion booked about $2.2 million of adjusted gross profit in the first half. Reaching even the low end means roughly $1.4 million a quarter for the rest of the year, against $1.2 million in the June quarter. The midpoint implies close to $1.9 million a quarter. Quarterly gross profit has risen every period, from $439,000 a year ago to $1.2 million. Even so, the third quarter needs a noticeable step up, not just another 20% gain, to make the second half look achievable without a heroic December.
The mix will show whether the business is healing. DeFi monetization had been the growth engine before it fell 36% to $158,000. A rebound there is the cleanest proof that the SKU and Entropy deals are working. Yield enhancement, which rose 58% to $334,000 on volatile hype trading, is the opposite case: impressive, but tied to market conditions that may not last. Ecosystem rewards have fallen three straight quarters to $90,000 and depend on airdrops. A fourth decline would surprise no one, but the guidance cannot afford a large hole there. The return over base staking yield, which slipped to 2.2 times from 3.1 times, is the simplest single scorecard. A recovery would support management's claim that the new deals pay better.
Costs offer more reliable help. Core operating expenses fell to $2.3 million from $4.3 million a year earlier, and management guided to a further 10% to 20% cut as the old biotech operations fully roll off. That implies roughly $1.85 million to $2.1 million this quarter. Investors should also look for early contributions from newer efforts, including the Avia institutional lending deal, the Blockdaemon staking partnership and the Risk Premium vaults, even if they are still small.
The market has been fairly generous. Shares are up 9.7% since the last report while the S&P 500 fell 2.7%. However, at $3.05 the stock sits below its 200-day average of $3.36 and in the lower half of its post-earnings range of $2.67 to $4.17, well off the highs. Sentiment has shifted from slightly bullish to slightly bearish, though both readings are close to neutral. In short, the stock has been rewarded but not with conviction.
The key question is simple. If adjusted gross profit clears roughly $1.4 million and DeFi monetization turns back up, the USDH episode looks like a stress test the company passed. If yield enhancement is again doing most of the work while the full-year target is merely repeated, the back-end-loaded guidance will start to look like hope rather than a plan.